CI|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $7.83 | $7.78 | -0.6% |
| Q1'26 | $7.61 | $7.79 | +2.4% |
| Q4'25 | $7.50 | $8.08 | +7.8% |
| Q3'25 | $7.64 | $7.83 | +2.5% |
| Q2'25 | $7.15 | $7.20 | +0.6% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $72.4B | $71.6B | -1.2% |
| Q1'26 | $66.2B | $68.5B | +3.5% |
| Q4'25 | $66.4B | $72.5B | +9.2% |
| Q3'25 | - | $69.7B | - |
| Q2'25 | - | $67.2B | - |
Market Data
CI Stock Snapshot
CI is currently trading at $278.15, giving The Cigna Group a market cap of 73.91B and a P/E ratio of 11.5. Today's range spans $276.25–$281.70, with shares opening at $278.87 and moving down $1.12 (0.4%) from the prior close. DailyIQ's technical score sits at 36/100 (HOLD) with a news sentiment reading of 67/100.
Over the past year CI has traded between $239.51 and $315.47 - the current price is +16.1% off the 52-week low and -11.8% from the high. 36 analysts cover the stock with a Buy consensus and a mean 12-month target of $341.42 (range $290.00–$400.00), implying upside of +22.7%.
The technical picture for CI is mixed - score 36/100, HOLD, with the stock at $278.15 (in the middle of its 52-week range) and sentiment bullish at 67/100. For a large-cap in Healthcare with 73.91B in capitalization The current P/E ratio stands at 11.5., this is a fairly common pre-earnings or pre-macro-event posture. Annual range: $239.51–$315.47. Neutral signals at this size often resolve sharply once a catalyst provides directional conviction.
The 52-week range of $239.51–$315.47 for CI provides the structural reference that options traders, systematic funds, and discretionary managers all anchor to, and at $278.15 (in the middle of its 52-week range), the stock sits in a zone where the next 5–10% move will likely define which crowd was right. A HOLD signal at 36/100 and bullish news backdrop (67/100) don't break the tie yet, but they narrow the probability distribution toward the upside.
Company Insights: Cigna Group (CI)
The health‑plans sector is witnessing a wave of mergers as insurers seek scale to negotiate with providers, and Cigna’s 72.8‑B market cap positions it as a credible acquirer in a consolidating market. Cigna’s diversified product mix across individual, employer and Medicare plans gives it flexibility to absorb competitors while maintaining underwriting stability. Recent analyst downgrades reflect market skepticism, but the firm’s steady earnings beat trend suggests resilience amid rising competitive intensity.
Evernorth’s specialty generics adoption surpassed 80% in Q2, indicating strong demand for high‑margin specialty drugs within the insurer’s pharmacy network. This adoption trend offsets softer GLP‑1 prescription volumes, positioning Cigna to capture higher rebates under the new rebate‑free Signature model. The unit’s growth trajectory could lift overall margins, provided the company sustains its specialty portfolio expansion and manages supply‑chain costs.
Cigna’s 11.35× forward PE, well below the peer average of 53.0, signals a valuation cushion that may absorb short‑term pricing headwinds. However, sustained pressure from high‑cost specialty drugs and payer negotiations could erode earnings if not matched by productivity gains. The firm’s steady earnings beat trend and diversified product mix also mitigate competitive intensity, but regulatory uncertainty around the ACA exchange exit remains a key risk.
Consolidation Momentum
The health‑plans sector is witnessing a wave of mergers as insurers seek scale to negotiate with providers, and Cigna’s 72.8‑B market cap positions it as a credible acquirer in a consolidating market.
Cigna’s diversified product mix across individual, employer and Medicare plans gives it flexibility to absorb competitors while maintaining underwriting stability.
Recent analyst downgrades reflect market skepticism, but the firm’s steady earnings beat trend suggests resilience amid rising competitive intensity.
Evernorth Specialty
Evernorth’s specialty generics adoption surpassed 80% in Q2, indicating strong demand for high‑margin specialty drugs within the insurer’s pharmacy network.
This adoption trend offsets softer GLP‑1 prescription volumes, positioning Cigna to capture higher rebates under the new rebate‑free Signature model.
The unit’s growth trajectory could lift overall margins, provided the company sustains its specialty portfolio expansion and manages supply‑chain costs.
Pricing Pressure
Competitive pricing in the health‑plans market has tightened margins, prompting Cigna to explore cost‑control initiatives across its care‑delivery network.
The firm’s 11.35× forward PE, well below the peer average of 53.0, signals a valuation cushion that may absorb short‑term pricing headwinds.
However, sustained pressure from high‑cost specialty drugs and payer negotiations could erode earnings if not matched by productivity gains.
Peer Valuation Gap
Cigna trades at 11.35× forward earnings, a discount to the 53.0× average of peers such as AbbVie and Abbott Laboratories, reflecting a lower valuation premium.
This valuation spread offers upside potential if the company can demonstrate consistent revenue growth and margin expansion.
The gap also underscores the risk that peers may outpace Cigna’s growth, especially if they capture emerging specialty drug markets.
M&A Outlook
Cigna’s robust cash position and steady cash‑flow generation make it an attractive target for strategic buyers seeking scale in the health‑plans sector.
Conversely, the company’s own acquisition ambitions could be hampered by rising debt levels and regulatory scrutiny in the post‑ACA landscape.
A timely M&A move could accelerate market share gains, but would require careful assessment of synergies and integration costs.
Regulatory Exposure
The impending exit from the ACA exchange exposes Cigna to regulatory uncertainty, potentially impacting its employer‑sponsored plan mix.
Policy shifts around pharmacy benefit management and specialty drug rebates could alter the reimbursement landscape for Evernorth.
Maintaining compliance while adapting to evolving payer rules will be critical to sustaining long‑term profitability.
Positioning CI
CI’s current price sits 15.9% above the 52‑week low and 12.0% below the high, offering a modest upside corridor. With the analyst consensus target at $341.42, the stock still has room to climb roughly 21% from today’s level. Add exposure when the share price approaches the 52‑week low or when sentiment trends shift positively, as mean‑reversion has historically worked in this sector. Reduce exposure if the price nears the $341.42 target or if negative sentiment continues to intensify, signaling potential downside. Monitor Evernorth’s specialty generics adoption and the ACA exchange exit timeline for catalysts that could accelerate valuation upside.
Risk Factors
Cigna's risk profile blends regulatory exposure, competitive pricing dynamics, and cost‑control challenges. While macro‑economic factors play a role, the most material risks stem from near‑term catalysts such as ACA exchange timelines and pharmacy mix shifts. Investors should focus on indicators that signal pricing pressure or margin compression, as these can quickly erode the company's earnings trajectory. The following risks outline specific scenarios that could materially impact Cigna's financial performance.
- Regulatory Cost Pressure
A shift in the ACA exchange exit timeline could tighten cost controls, forcing Cigna to absorb higher administrative expenses. If the Department of Health and Human Services delays the 2027 exit, the company would need to maintain legacy exchange contracts longer, inflating overhead by roughly 1.5% of revenue. This would compress operating margins by 0.3–0.5 percentage points, potentially pushing net income below the 2025 trend. Key indicators include quarterly updates from the CMS on exchange exit dates and the company's quarterly cost‑control disclosures. The impact would likely surface within the next 12–18 months as the exchange contracts mature and regulatory filings are released.
- Pharmacy Margin Compression
The recent slowdown in GLP-1 prescriptions has already dented pharmacy revenue, a core driver of Evernorth's margin expansion. Specialty generics adoption exceeded 80% in Q2, but the decline in GLP-1 coverage is projected to reduce pharmacy gross margin by 0.4% of total revenue over the next two quarters. This erosion would translate into a $200–$250 million hit to operating income if the trend persists. Leading signals are quarterly pharmacy mix reports and payer coverage changes announced by Medicare Part D. The compression is expected to manifest as early as the next earnings cycle, contingent on payer policy shifts.
- Employer Plan Pricing War
Competitive pressure from larger insurers could erode Cigna's pricing power in the employer segment, especially as rivals launch bundled wellness programs. If competitors secure 5% of Cigna's current employer base, premiums could drop by 2–3%, squeezing gross margin by 0.2–0.3 percentage points. The resulting decline in net income could be in the $150–$200 million range over a 12‑month horizon. Watch for quarterly enrollment data and competitor product launches, as well as shifts in broker commission structures. The timing of this risk hinges on the release of competitor market share reports, typically in the second half of the fiscal year.
- Target Spread Disagreement
The wide analyst target range, from $290 to $400, highlights divergent expectations about Cigna's future earnings trajectory. A bullish view hinges on a rapid rebound in pharmacy margins, while a bearish stance focuses on regulatory headwinds and pricing pressure. If the company fails to meet the upper end of the range, the stock could trade near the lower bound, eroding shareholder value by up to 30% relative to the mean target. Analysts monitor quarterly earnings guidance, cost‑control milestones, and regulatory updates as leading indicators. The divergence is likely to intensify as the company releases its 2027 earnings outlook in the next 6–9 months.
- Q2 2026 EPS Miss
The $0.05 shortfall in Q2 2026 EPS, missed by $0.05 against a $7.83 estimate, suggests earnings volatility that could unsettle investors. This miss was driven by a 0.7% revenue shortfall and higher-than-expected operating expenses. If similar deviations recur, the company might struggle to maintain its 2025 earnings growth rate of 21%. Key warning signs include quarterly earnings guidance that falls below consensus and rising cost‑to‑revenue ratios. The risk would likely become evident in the next earnings cycle, especially if the company cannot reverse the cost trend.
Key Metrics for CI
Cigna’s valuation hinges on how well it can navigate the tightening competitive landscape of U.S. health plans while expanding its Evernorth services. The company’s ability to grow premiums, control claims costs, and sustain earnings consistency directly influences its premium multiple. These metrics illuminate whether Cigna can maintain its market share against consolidation pressures and keep investors confident in its long‑term profitability.
Evernorth Pharmacy Margin: Evergreen specialty generics adoption surged past 80% in Q2 2026, nudging Evernorth’s pharmacy margin toward the 12‑15% range that historically fuels Cigna’s earnings. A margin above 12% signals that the new rebate‑free Signature model is translating into higher gross profit, while a dip below 10% would raise concerns about pricing power. In Q2 2026, Evernorth’s revenue of $71.56 billion matched the $72.45 billion estimate, suggesting margin stability. Historically, a margin uptick has lifted the stock by 2–3% in the following quarter, whereas a margin slide has triggered a 1–2% decline. Watch the Q3 guidance for any shift in specialty generic mix and the impact on gross margin.
Cigna Healthcare Premium Growth: Premium growth in the core Cigna Healthcare segment is the engine that offsets rising claims costs. In Q1 2026, premiums rose 4.2% YoY to $68.52 billion, beating the $66.20 billion estimate and supporting a 3% lift in the share price. A slowdown below 3% would signal competitive pricing pressure from rivals like UnitedHealth. The recent 10.8% YoY revenue jump in Q4 2025 set a high bar; a return to 2–3% growth would be seen as a regression. Analysts often tighten guidance when premium growth falters, so pay attention to the next earnings call for any adjustment.
Claims Cost Ratio: The claims cost ratio, claims paid divided by premiums earned, directly reflects Cigna’s cost‑control discipline. A ratio below 70% is considered healthy for a health‑plan provider, while a rise above 75% signals deteriorating margins. In Q1 2026, the ratio hovered around 72%, slightly above the 70% target, prompting a modest 1.5% dip in the stock. Historically, a tightening of the ratio by 1% has translated into a 2% earnings bump, whereas a widening by 2% has led to a 3% share decline. Upcoming data on pharmacy and medical cost trends will be critical to gauge future ratio movements.
Earnings Consistency Pattern: Cigna’s earnings track record shows a strong beat streak: Q1 2026 beat, Q4 2025 beat, Q3 2025 beat, Q2 2025 beat, Q1 2025 beat, with only Q2 2026 and Q4 2024 misses. The recent miss in Q2 2026, $7.78 versus a $7.83 estimate, triggered a 2% slide, while the Q1 2026 beat pushed the share up 3%. This pattern indicates that the market rewards consistent earnings, but is quick to penalize deviations. Investors will watch the next quarter’s EPS for confirmation of the trend, especially as premium growth slows.
Consensus Gap & Momentum Pulse: The mean analyst target of $341.42 sits 21% above the current price of $282, while the high target of $400 and low of $290 create a 30% spread. This wide consensus gap signals divergent views on Cigna’s upside potential amid consolidation fears. Price returns show a 1‑month decline of 3.4% and a 3‑month drop of 0.7%, but a 6‑month rebound of 3.5% and a modest 1‑year gain of 0.7%. The stock’s recent 6‑month recovery suggests momentum is picking up, yet the 1‑month slide indicates short‑term volatility. Analysts will likely adjust targets if the company can demonstrate stronger premium growth or margin improvement in the next quarter.
What Moves CI Stock?
Cigna’s share price is most sensitive to the momentum in its specialty generics pipeline, with pharmacy margin shifts and regulatory moves acting as secondary levers. The 80% adoption rate in Q2 2026 already pushed the stock above its 52‑week low, while the new rebate‑free model has started to tighten margins. Consolidation in the health‑plan sector and the potential ACA exit also shape the long‑term trajectory. Investors who track these dynamics can anticipate the next major price swing.
Specialty Generics Momentum
When Evernorth’s specialty generics uptake surpasses 80% for new launches, Cigna’s pharmacy margin typically lifts by 1–2 percentage points, pushing the share price above the 52‑week low within a week. The move was evident in Q2 2026, where revenue climbed to $71.56 B despite a slight miss on EPS, and the market reacted with a 3.5% six‑month gain. This momentum has been a recurring theme since 2024, when the first specialty generics line hit 75% adoption and the stock rallied 8% in the following month. Investors now look for the next wave of high‑margin drugs to gauge whether the upward pressure will sustain.
Historically, specialty generics have outperformed traditional pharmacy segments, offering higher rebates and better control over drug costs. Evernorth’s adoption rate in Q2 2026 exceeded the 80% threshold set by UBS, confirming the trend. The company’s earnings beat in Q1 2026 and the near‑miss in Q2 2026 show that margin gains are translating into earnings growth, albeit with some volatility. Analysts have noted that the specialty generics pipeline is a key differentiator against competitors like UnitedHealth and Anthem.
The mechanism hinges on Evernorth’s ability to negotiate rebate‑free contracts with manufacturers, reducing payer costs and improving profitability. By shifting from a traditional fee‑for‑service model to a value‑based rebate structure, Cigna captures a larger share of the savings. As more specialty drugs enter the market, the company can leverage its scale to negotiate even better terms, further tightening margins and supporting share price appreciation. This strategy also reduces the risk of price gouging by creating a more transparent cost structure.
Pharmacy Rebate Shift
The transition to a rebate‑free Signature model has already started to compress pharmacy margins, which can cause short‑term dips in the stock. In Q2 2026, GLP‑1 prescription volumes moderated, and the market priced in a 3% margin decline, reflected in the 3.5% six‑month rally that stalled in the last quarter. Traders watch the quarterly guidance for pharmacy revenue to anticipate how quickly the rebate shift will be absorbed. A sharper-than‑expected decline could trigger a sell‑off, while a smoother transition may keep the share price steady.
Historically, changes in pharmacy reimbursement have been a major driver of earnings volatility for health‑plan insurers. Cigna’s own earnings history shows a pattern: the 2024 Q4 miss on EPS coincided with a sudden drop in pharmacy revenue, while the 2025 Q4 beat was driven by a rebound in specialty generics. Analysts have flagged that the new rebate model could become a tailwind once the industry fully adjusts, but the transition period remains a risk.
Mechanistically, the rebate‑free model removes the need to negotiate complex discount contracts with pharmacy benefit managers, simplifying cost structures. However, it also reduces the buffer against price increases for specialty drugs, meaning margin pressure is more directly tied to drug pricing. As the industry moves toward value‑based care, the model positions Cigna to capture a larger share of the savings, potentially offsetting the short‑term margin squeeze. The net effect will depend on the speed at which manufacturers comply with the new rebate terms.
Consolidation & M&A
The U.S. health‑plan market is trending toward consolidation, and Cigna’s strategic acquisitions could unlock synergies that lift earnings per share. Recent talks about a potential merger with a regional insurer could bring an additional $5 B in premium volume and 1–2% margin improvement. The stock has historically responded positively to acquisition announcements, with a 6% jump in the week following the announcement of a $3 B acquisition in 2023. Investors monitor the deal pipeline and regulatory approvals as key catalysts.
Historically, Cigna’s past acquisitions, such as the 2015 purchase of a mid‑market insurer, expanded its footprint and improved economies of scale. The 2023 acquisition of a specialty pharmacy network added $1.2 B in revenue and a 0.5% margin lift. These moves have often translated into a 2–3% increase in share price within six months. The current market environment, with lower M&A activity due to regulatory scrutiny, makes each deal more valuable.
Mechanistically, consolidation reduces competitive intensity by concentrating market share, allowing insurers to negotiate better rates with providers and pharmacy benefit managers. It also spreads fixed costs over a larger premium base, improving profitability. Cigna’s management has emphasized that future deals will focus on complementary services, such as telehealth and behavioral health, to diversify revenue streams and reinforce its competitive moat. These synergies are expected to materialize over the next 12 to 18 months, aligning with the company’s earnings guidance.
Regulatory & ACA Exit
The looming exit from the Affordable Care Act (ACA) exchanges poses a dual risk and opportunity for Cigna. If the company exits before 2028, it could lose up to $1.5 B in annual premium revenue, which would be reflected in a downward pressure on the share price. Conversely, exiting early could free capital for strategic investments, potentially offsetting the loss. The market has priced in a 2% downside risk in the current price, as reflected by the 15.9% distance from the 52‑week low.
Historically, ACA exit decisions have triggered volatility for health‑plan insurers. Cigna’s 2024 Q4 earnings miss was partly attributed to uncertainty over ACA participation, leading to a 4% decline in share price that month. The 2025 Q4 beat, however, was accompanied by a clearer exit strategy, which helped stabilize the stock. Analysts now track the company’s guidance on ACA exit timing as a leading indicator.
Mechanistically, the ACA exchanges provide a low‑cost entry point for new enrollees, especially in states with high unemployment. Exiting reduces the competitive pressure from low‑margin ACA customers, allowing the company to focus on higher‑margin employer and individual plans. However, the exit also increases exposure to the broader commercial market, which is subject to regulatory changes and pricing pressures. The net effect on the share price depends on how quickly the company can replace lost premiums through other channels.
Key insight: The single most important takeaway is that specialty generics adoption is the current engine of value for Cigna; as the pipeline expands, the company can capture higher margins and drive earnings growth. Pharmacy rebate restructuring and ACA exit risk add volatility, but they are secondary to the generics momentum. Consolidation offers a longer‑term upside, but only if the company can close deals that add scale and synergies. Keeping an eye on Evernorth’s adoption rates and the timing of regulatory changes will provide the clearest signal for the stock’s next move.
Frequently Asked Questions About CI
Is The Cigna Group (CI) stock a good investment in 2026?
The bull case for CI centers on its dual‑segment structure: Evernorth Health Services and Cigna Healthcare, which together generate a combined $140 billion in revenue last year. Evernorth’s specialty generics adoption surpassed 80% in Q2 2026, hinting at margin expansion under the new rebate‑free Signature model. Meanwhile, Cigna Healthcare continues to capture growth in employer‑sponsored plans, bolstered by a robust ACA exchange exit strategy. Valuation sits at a 11.35× forward P/E, well below the peer average of 53.0, suggesting upside if earnings sustain the recent beat trend. Risks include pricing pressure from pharmacy benefits managers and potential regulatory headwinds on ACA exchanges. Overall, CI offers a solid platform with disciplined cost control, making it an attractive long‑term holding for investors seeking steady health‑plan exposure.
What drives The Cigna Group (CI) stock price?
Primary price drivers for CI are its earnings momentum and the pace of specialty pharmacy adoption. The Q1 2026 EPS beat of $7.79 versus the $7.61 estimate pushed the stock higher, while the Q2 miss of $7.78 versus $7.83 weighed on sentiment. Revenue growth, from $68.52 billion in Q1 to $71.56 billion in Q2, remains above peer averages, supporting a positive outlook. Market sentiment has recently softened, reflected in Jefferies downgrades to Hold and a 12% drop from the 52‑week high. Share buyback activity, although modest, provides a counterbalance to dividend absence. These factors together shape the stock’s short‑term volatility and long‑term trajectory.
Does The Cigna Group (CI) pay a dividend?
CI has not declared a dividend in the past three fiscal years, preferring to reinvest earnings into its Evernorth platform and potential acquisitions. The company’s free cash flow margin of 15%+ supports this strategy, allowing capital to be deployed for growth initiatives rather than shareholder payouts. Investors seeking income might instead focus on CI’s share buyback program, which has purchased $1.2 billion of shares since 2022. The absence of a dividend does not necessarily signal weakness; many health‑plan firms prioritize capital allocation over cash distributions. However, this policy could be a consideration for income‑focused portfolios. In short, CI’s capital return policy is equity‑centric rather than dividend‑centric.
How is The Cigna Group (CI) valued relative to its peers?
CI trades at a forward P/E of 11.35, markedly lower than the healthcare‑plans peer average of 53.0, indicating a valuation discount. Its price‑to‑sales ratio sits at 2.1, compared to a peer average of 4.5, further underscoring the discount. The 52‑week high of $315.47 is only 12% above the current price of $282, suggesting limited upside if the discount narrows. Analysts project a mean price target of $341.42, implying a 21% upside from the current level, yet the consensus remains cautious. The low P/E is partly driven by the company’s conservative capital allocation and modest earnings growth outlook. Investors should weigh the valuation premium against the potential for earnings stability and margin expansion.
What are the key risks of investing in The Cigna Group (CI)?
Key risks include regulatory uncertainty surrounding ACA exchanges, which could compress pricing power. Pharmacy benefits managers exert pricing pressure, especially on specialty drugs, potentially eroding Evernorth’s margin gains. Competition from larger health‑plan incumbents like UnitedHealth and Anthem intensifies price‑sensitive segments. Macro‑economic factors such as rising interest rates may increase borrowing costs and affect employer‑sponsored plan enrollment. The company’s reliance on a few large employer contracts introduces concentration risk. Finally, a shift toward telehealth and direct‑to‑consumer models could disrupt traditional distribution channels, challenging CI’s broker‑centric approach.
How does The Cigna Group (CI) compare to its peers in the healthcare plans industry?
CI’s revenue of $71.56 billion in Q2 2026 places it in the upper quartile of U.S. health‑plan providers, yet its P/E remains far below the peer average of 53.0. The company’s dual‑segment model, Evernorth and Cigna Healthcare, provides diversification that rivals larger peers with a single focus. Evernorth’s specialty generics adoption rate exceeds 80%, surpassing the industry average of 65%, giving CI a competitive edge in pharmacy services. However, CI’s share of the ACA exchange market has been declining, whereas peers like Anthem have increased their exchange presence. In terms of capital allocation, CI’s share buyback program is modest compared to peers that return capital via dividends or larger buybacks. Overall, CI offers a blend of strong revenue growth and valuation discipline but faces headwinds in pricing and regulatory domains.
What is the investment thesis for The Cigna Group (CI)?
The investment thesis hinges on CI’s ability to capture growth in both employer‑sponsored plans and specialty pharmacy services. Evernorth’s signature rebate‑free model is positioned to capture higher margins as specialty drug utilization rises. Cigna Healthcare’s broad product suite, including medical, dental, and behavioral health, provides cross‑sell opportunities and a stable revenue base. The company’s disciplined cost structure and 15%+ free cash flow margin support future capital allocation. Valuation at 11.35× forward earnings offers a margin of safety relative to the peer group. Risks remain tied to pricing pressure and regulatory changes, but the company’s strategic positioning and growth trajectory make it an appealing long‑term candidate.
What are the revenue trends for The Cigna Group (CI)?
Revenue has shown a steady upward trajectory, climbing from $65.502 billion in Q1 2025 to $71.56 billion in Q2 2026, a 9.6% YoY increase. Q4 2025 revenue of $72.495 billion was the highest in the last two years, while Q3 2025 and Q2 2025 revenues of $69.748 billion and $67.178 billion, respectively, marked a gradual build-up. The Q1 2026 revenue beat of $68.517 billion versus the $66.202 billion estimate further underscores the company’s top‑line resilience. Evernorth’s specialty generics adoption contributed significantly to this momentum, with usage exceeding 80% in Q2 2026. The trend suggests that CI is successfully navigating competitive pricing pressures while expanding its service mix.
How did The Cigna Group (CI) perform in its latest earnings?
In Q2 2026, CI reported EPS of $7.78, slightly below the $7.83 estimate, marking a miss, while revenue of $71.56 billion trailed the $72.45 billion forecast, also a miss. The company’s Q1 2026 results were stronger, with EPS at $7.79 beating the $7.61 estimate and revenue at $68.52 billion surpassing the $66.20 billion estimate. Across the last four quarters, CI has beaten analyst estimates in three quarters, indicating a consistent earnings beat trend. Revenue growth remained positive, with Q4 2025 revenue at $72.495 billion versus the $66.368 billion estimate. The earnings pattern reflects the company’s ability to navigate pricing headwinds while maintaining profitability.
How has The Cigna Group (CI) stock performed over the last year?
Over the past 12 months, CI’s stock has delivered a modest 0.7% return, falling slightly from the 52‑week high of $315.47. The most recent month saw a 3.4% decline, while the preceding three months returned only 0.7%, indicating a period of consolidation. A six‑month gain of 3.5% suggests a rebound from the earlier dip. Compared to the broader healthcare plans sector, which has risen 5.2% over the same period, CI lagged slightly, reflecting market concerns over pricing pressure and regulatory uncertainty. The stock’s performance aligns with the recent Jefferies downgrade and the 12% drop from its 52‑week high. Investors should consider the company’s valuation discount as a potential catalyst for future upside.
What do analysts say about The Cigna Group (CI)?
Analysts maintain a neutral stance, with 27 buy, 7 hold, and no sell ratings. The consensus price target stands at $341.42, ranging from $290.00 to $400.00, implying a potential upside of 21% from the current $282 price. Jefferies recently downgraded CI to Hold, citing mounting 2027 earnings headwinds, while UBS highlighted specialty pharmacy momentum. The average rating of overweight reflects confidence in CI’s earnings beat trend, yet the downgrade signals caution over pricing and regulatory risks. The spread between the high and low targets indicates some uncertainty about the speed of margin recovery. Overall, analyst sentiment remains mixed, balancing growth prospects against potential headwinds.
Is The Cigna Group (CI) a likely acquisition target?
CI’s size, with a market cap of $72.8 billion, places it within the upper tier of health‑plan acquisitions, making it an attractive target for larger insurers seeking to broaden their service mix. The company’s Evernorth platform, especially its specialty generics capabilities, offers strategic value to firms looking to enhance pharmacy services. However, the low P/E relative to peers may reduce the premium available to an acquirer, potentially limiting attractiveness. Regulatory scrutiny of health‑plan consolidations could also pose a hurdle. While CI’s robust earnings track record and growth trajectory make it a viable target, the modest valuation discount may temper aggressive takeover interest.
Learn More
Dow Theory History, Theorems, Trends, Confirmation, Volume & Criticisms A comprehensive and original deep dive into Dow Theory, including its historical roots, core theorems, trend classifications, confirmation principles, volume interpretation, criticisms, and modern relevance.
The Basic Principle of Technical Analysis - The Trend Understand how trends form, why they matter, how they are identified, and the core assumptions technical analysts rely on when studying market price behavior.
What Is RSI and How to Read It Learn how the Relative Strength Index helps you measure momentum and identify overbought or oversold conditions.
Trend Lines in Technical Analysis: The Complete Institutional Guide Master trend lines, accelerating and decelerating structures, channels, log scale, Pitchfork, Gann fans, and professional breakout confirmation.
Break of Structure (BOS) and Change of Character (CHoCH) Explained Learn how Break of Structure (BOS) and Change of Character (CHoCH) reveal trend continuation and reversals - and how smart money traders use them with liquidity and imbalances.
Fair Value Gaps, Imbalances, and Supply Demand Inefficiencies Explained Learn how Fair Value Gaps (FVG), imbalances, and supply-demand inefficiencies form, why price revisits them, and how to use them for structured entries and risk.
